In their letter to the Editor about our review article (and not "narrative article") Nalmpantidis and Maris mention a meta-analysis [1] in which results with probiotic preparation VSL#3 in pouchitis are not included [2] [3] [4] , suggesting their limited value. The authors concluded that there is an urgent need for a large, placebo-controlled trial on this topic.
They should have considered the Cochrane meta-analysis on treatment and prevention of pouchitis [5] , in which all studies, where VSL#3 was used, were included and were considered the most appropriate and the best performed with clear evidence of the efficacy of VSL#3 both in the prevention of pouchitis onset and in the maintenance treatment of remission.
Furthermore, based on the results of these studies, the ECCO Consensus has suggested the use of VSL#3 in both indications [6] .
